| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143163 | Lung Cancer | 2008 | 6 Pages |
Abstract
Adding cisplatin to vinorelbine treatment is feasible in elderly patients, and has a better response rate and longer median time to disease progression. However, both statistically significantly higher toxicity and no survival advantage for the combination treatment was observed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Jacqueline Whang-Peng,